Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis

NCT ID: NCT00301002

Last Updated: 2006-11-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-06-30
• Study Completion Date: 2006-10-31

Brief Summary

The purpose of this study is to determine if Alefacept is effective in the treatment of palmar plantar pustulosis.

Detailed Description

Palmar plantar pustulosis is a chronic, disabling skin condition which is difficult to treat since it is often recalcitrant to current treatments and associated with high recurrence rates. This condition appears to be a T lymphocyte mediated condition and is thought by some to be a subtype of psoriasis. Alefacept affects T cell activation and induces apoptosis of memory T cells. It has been shown to be efficacious in the treatment of psoriasis vulgaris and may be associated with prolonged remissions. There is extremely limited experience with use of Alefacept in Palmar Plantar Pustulosis. This pilot trial should provide additional information concerning its use for this indication.

Conditions

Psoriasis; Palmoplantaris Pustulosis; Pustular Psoriasis of Palms and Soles; Pustulosis Palmaris et Plantaris; Pustulosis of Palms and Soles

Keywords

safety; effectiveness; Alefacept; Palmar; Plantar; Pustulosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Alefacept

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects must have stable, moderate, severe or very severe palmar plantar pustulosis.
• Must have a minimum of at least 3 pustules on 1 sole or palm.
• Must give written informed consent.
• Subjects must be 18 years of age or older.
• Adult Males and non-pregnant, non-lactating females.
• Female subjects of childbearing potential must state that they are using measures to avoid conception through active means.
• Subjects must be in general good health with no other skin disease, disease state or physical condition which would impair evaluation of palmar plantar pustulosis or which would increase their health risk by study participation.
• Subjects must be willing to receive a 15 mg IM injection of Alefacept weekly for 16 weeks.

Exclusion Criteria

• Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
• Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy.
• Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug.
• Any subject whose CD4+ T-lymphocyte count at study entry is less than the lower limit of normal per reference laboratory.
• Treatment with another investigational drug or approved therapy for investigational use within 28 days prior to investigational drug administration.
• Treatment with psoralen + ultraviolet A (PUVA), systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab, adalimumab or mofetil or other systemic immunosuppressant agents within the 28 days prior to investigational drug administration.
• Ultraviolet B (UVB) phototherapy within 14 days prior to investigational drug administration.
• Treatment within 7 days with topical agents (e.g. tar, anthralin, calcipotriol, tazarotene, steroids) which might have an effect on palmar plantar pustulosis.
• Known HIV, Hepatitis B or C seropositivity or tuberculosis infection.
• Significant abnormal chemistry, i.e. liver function tests greater than 3 times the upper limit of normal.
• Allergy to Alefacept or any of the components of the formulation.
• Known malignancy or history of malignancy within the previous 5 years (with the exception of basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin that has been treated with no evidence of recurrence.)
• Previous treatment with alefacept.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biogen

INDUSTRY

Sponsor Role: collaborator

The Guenther Dermatology Research Centre

OTHER

Sponsor Role: lead

Principal Investigators

Lyn C Guenther, MD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

The Guenther Dermatology Research Centre

Locations

The Guenther Dermatology Research Centre

London, Ontario, Canada

Countries

Canada

Other Identifiers

IST 92

Identifier Type: -

Identifier Source: org_study_id